




Blood pressure increases with aging only in civilizations with high salt intake



Comparative international data on salt intake and blood pressure levels at varying ages (data from MacGregor with permission.)




Cook islands

- Difference in BP and HT between highland and coast
- emigrants to Hawaii – prevalence of HT higher (30%)

ANIMAL ANALOGY


- Philogenetic similarities
- 99.6% coding exons
- Same amount of NaCl in milk
- no stress, same potassium intake
- BP increase with higher salt intake
- salt sensitivity in chimpanzees



Denton, 1995

Correlation between blood pressure and salt intake

Salt intake determines BP in hypertensive and normotensive subjects




Cutler, 1997

INTERSALT study


Δ intake NaCl 100 mmol = Δ BP of 10/6 mmHg/30 years

Correlation of systolic AMBP and salt intake in Croatia




Correlation of systolic AMBP and salt intake in Croatia


**Normotension
(N= 62)**




**White coat HT
(N=64)**




**Essential HT
(N=55)**



24 hour sodium excretion (mmol/dU) and BP categories in Croatia







Alimentary,

My Dear Watson




Guytons' Pressure-Natriuresis relationship



Interaction of the Modern Western Diet and the Kidneys in the Pathogenesis of Essential Hypertension




Final, common pathway in hypertension



HYPERTENSION

Renal mechanisms of diminished sodium excretion



Molecular error
in sodium transport

Less nephrons

Decreased medullary
circulation

Loss of peritubular blood vessels
and interstitial fibrosis

Renal mechanisms of diminished sodium excretion

Mechanisms

Reduced ultrafiltration capability


Enhanced tubular Na reabsorption

Disorders

Chronic kidney disease
Hypertension in blacks
Sodium sensitive EH

Primary aldosteronism
Diabetes mellitus
Metabolic syndrome

Hypertension 'follows' a transplanted kidney





REMISSION OF ESSENTIAL HYPERTENSION AFTER RENAL TRANSPLANTATION

JOHN J. CURTIS, M.D., ROBERT G. LUKE, M.B. CH.B., HARRIET P. DUSTAN, M.D., MICHAEL KASHGARIAN, M.D., JOHN D. WHELCHER, M.D., PATRICIA JONES, R.N., AND ARNOLD G. DIETHELM, M.D.

Table 1. Clinical Characteristics and Results of Blood-Pressure and Renal-Function Studies the First Time Both Were Obtained Simultaneously in the Six Black Patients with a Family History of Hypertension (See Appendix).*

PATIENT No.	AGE/SEX	BLOOD PRESSURE <i>mm Hg</i>	SERUM BUN/CREATININE <i>mg/dl</i>	URINARY PROTEIN	No. OF YEARS BEFORE ESRD THERAPY
1	29/M	240/170	13/1.3	100 mg/24 hr	4
2	36/M	180/150	23/1.7	Negative by dipstick	1.5
3	30/F	150/100	12/1.0	Negative by dipstick (<100 mg/24 hr)	5
4	27/M	185/120	35/— †	Negative by dipstick	2
5	38/F	150/100	10/0.4 (during pregnancy)	360 mg/24 hr	2
6	24/M	300/160	28/2.8	600 mg/24 hr	0.2

*BUN denotes blood urea nitrogen level, and ESRD end-stage renal disease.

†Creatinine not measured.

with comments by

ROBERT G. LUKE, AND EBERHARD RITZ
N. Engl. J. Med. 309:1009-1015, 1983



Table 2. Evidence of Resolution of Cardiac Hypertrophy from Electrocardiograms and Chest X-Ray Films before and after Renal Transplantation.

PATIENT No.	SCORE FOR VENTRICULAR HYPERTROPHY *		DIAMETER OF HEART †	
	BEFORE	AFTER	BEFORE	AFTER
	<i>centimeters</i>			
1	4	0	16.8	13.2
2	6	0	17.0	13.0
3	6	0	16.2	13.5
4	3	0	17.3	14.2
5	6	0	16.8	14.8
6	7	2	18.0	14.0
Mean ± S.E.M.	5.3 ± 0.6	0.3 ± 0.3	17.0 ± 0.2	13.8 ± 0.3
	(P < 0.001)		(P < 0.001)	





Figure 1. Photomicrograph of the Nephrectomy Specimen from a Patient Typical of Those Considered to Have Nephrosclerosis.

Monogenic hypertensions & hypotensions





Modifi. after Lifton et al, Cell 2001

Central Role for ENaC in Development of Hypertension

J. Howard Pratt


J Am Soc Nephrol 16: 3154–3159, 2005.





Increased sodium absorption in renal tubules:

- Hypertrophy of cardiomyocytes and VSM in blood vessels
- Enhanced expression of AT1 receptor
- Activation of NF- κ B in proximal tubule (inflammation)
- Enhanced stimulation of central sympathetic (via Ang II)
- Increased synthesis of TGF beta
- Increased NAD(P)H – oxidative stress – inflammation
 - less NO
 - diminished medullary flow



Increased sodium intake = increased total cardiovascular risk

- **increased reactivity of platelets**

→ *via Na:Ca exchanger*

Gow, 1992, Nara, 1984

- **increased hypertrophy and fibrosis**

→ *via TGF β*

Gu, 1998

- **\uparrow expression of AT1 R and \downarrow AT2 R**

→ *via local RAS*

Schmid, 1997

- **\uparrow ET 1**

Ferri, 1997

- **endothelial dysfunction**

→ *via NO, EDHF*



Miyoshi, 1997

- **\uparrow insulin resistance**

Campese, 1994

**Increased sodium intake = increased total cardiovascular risk,
independently of blood pressure**

Sodium excretion and left ventricle hypertrophy and albuminuria



Salt-sensitive hypertension—update on novel findings

Bernardo Rodriguez-Iturbe¹ and Nosratola D. Vaziri²

Nephrol Dial Transplant (2007) 22: 992–995




Fig. 1. A simplified comparison of salt-sensitive hypertension (1960–70's vs. 2000's).

No kidney,

No cry !


**KEMPNER W, PESCHEL E, STARKE H. Rice diet in malignant hypertension
; a case history.**

Am Pract Dig Treat. **1949** May;3(9):556-63.

KEMPNER W.

**Treatment of heart and kidney disease and
of hypertensive and arteriosclerotic vascular disease
with the rice diet.**

Ann Intern Med. **1949** Nov;31(5):821-56,




Since the 1930s, Kempner and his associates have employed the Rice Diet to treat more than 18,000 patients from all around the world.

Walter Kempner retired from Duke University in 1974 and from the Rice Diet program in 1994.


He died in 1997 at the age of 93.

DASH Sodium Trial



DASH-Sodium Trial (N.I.H.)


All participants (N = 412)




Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP)

Nancy R Cook, associate professor,¹ Jeffrey A Cutler, former senior scientific adviser,² Eva Obarzanek, research nutritionist,² Julie E Buring, professor,³ Kathryn M Rexrode, assistant professor of medicine,¹ Shiriki K Kumanyika, professor of epidemiology,³ Lawrence J Appel, professor of medicine,⁴ Paul K Whelton, president and chief executive officer,⁵ for the Trials of Hypertension Prevention Collaborative Research Group

Long term effects (after 15 years) of 3 g lower salt intake



Cardiovascular risk 25% by sex, and clinic



Total mortality 20% in TOHP I

Wisdom begins in wonder.

Socrates

